A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents.

With the aim of inhibiting cancer growth and reducing the risk of metastasis, pharmaceutical companies in the early 1990s developed anti-metastatic agents called inhibitors of metalloproteinases (MMPi). Despite the promising results obtained in pre-clinical studies, results of Phase III trials have been somewhat disappointing for late stage cancer patients. With the aim of mathematically investigating this therapeutic failure, we developed a mechanistically based model which integrates cell cycle regulation and macroscopic tumor dynamics. By simulating the model, we evaluated the efficacy of MMPi therapy. Simulation results predict the lack of efficacy of MMPi in advanced cancer patients. The theoretical model may aid in evaluating the efficacy of anti-metastatic therapies, thus benefiting the design of prospective clinical trials.

[1]  Z. Agur,et al.  A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth , 2004, Angiogenesis.

[2]  Philip Hahnfeldt,et al.  Simple ODE models of tumor growth and anti-angiogenic or radiation treatment , 2001 .

[3]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[4]  Z. Agur,et al.  Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. , 2005, European journal of cancer.

[5]  Z. Agur,et al.  The growth law of primary breast cancer as inferred from mammography screening trials data. , 1998, British Journal of Cancer.

[6]  G. Taraboletti,et al.  Preclinical development of metalloproteasis inhibitors in cancer therapy. , 2001, Critical reviews in oncology/hematology.

[7]  J. Folkman,et al.  Role of cell shape in growth control , 1978, Nature.

[8]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[9]  S. Roberts,et al.  Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine. , 1992, Gut.

[10]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[11]  S. Schnell,et al.  A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies , 2006, Theoretical Biology and Medical Modelling.

[12]  Maria Pavlaki,et al.  Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials , 2003, Cancer and Metastasis Reviews.

[13]  M. Loeffler,et al.  Modeling the effect of deregulated proliferation and apoptosis on the growth dynamics of epithelial cell populations in vitro. , 2005, Biophysical journal.

[14]  H. Greenspan.  Models for the Growth of a Solid Tumor by Diffusion , 1972 .

[15]  L. Preziosi,et al.  ON THE CLOSURE OF MASS BALANCE MODELS FOR TUMOR GROWTH , 2002 .

[16]  P K Maini,et al.  A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results , 2005, Bulletin of mathematical biology.

[17]  S. Zucker,et al.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment , 2000, Oncogene.

[18]  P. C. Weaver,et al.  Proliferation characteristics of human colorectal carcinomas measured in vivo , 1991, The British journal of surgery.

[19]  I D Bassukas,et al.  Comparative Gompertzian analysis of alterations of tumor growth patterns. , 1994, Cancer research.

[20]  P. Skehan,et al.  Deceleratory growth by a rat glial tumor line in culture. , 1982, Cancer research.

[21]  T E Wheldon,et al.  THE GOMPERTZ EQUATION AND THE CONSTRUCTION OF TUMOUR GROWTH CURVES , 1980, Cell and tissue kinetics.

[22]  Mikhail V. Blagosklonny,et al.  The Restriction Point of the Cell Cycle , 2002, Cell cycle.

[23]  H. Greenspan.  On the growth and stability of cell cultures and solid tumors. , 1976, Journal of theoretical biology.

[24]  J. Verweij,et al.  Matrix metalloproteinase inhibitors: current developments and future perspectives. , 2001, The Oncologist.